Novus Biologicals adds new PKM2 antibody to their antibody catalog

Novus Biologicals' new PKM2 antibody (NBP1-48308) is useful for the study of cancer metabolism and bacterial pathogenesis.  This rabbit polyclonal anti-PKM2 antibody cross-reacts with bovine, human, mouse and rat and has been validated for use in immunocytochemistry and Western blot. By Western blot on HeLa whole cell extract, a band at ~60kDa is seen.

The immunogen to which Novus' new PKM2 antibody was made is a synthetic peptide made within residues 350-450 of the human PKM2 protein [Swiss-Prot# P14618]. PKM2 is localized to the cytoplasm, but translocates to the nucleus in response to different apoptotic stimuli.

PKM2 is a pyruvate kinase that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate (PEP) to ADP, generating ATP and pyruvate.  In cancer cells, PKM2 is not very active, causing PEP to accumulate. This buildup of PEP then activates an enzyme called PGAM , which catalyzes an earlier step in glycolysis. When PGAM is activated as such, it produces even more PEP, creating a positive feedback loop (the more PEP in a cell, the more PEP the cell makes). Drugs that activate PKM2 could be promising cancer treatments; if PKM2 were highly activated, cancer cells would alter PEP metabolism, blocking the alternative pathway and hindering the production of new building blocks (PMID: 20847263). PKM2 interacts with thyroid hormone , thus may mediate cellular metabolic effects induced by such hormones. PKM2 has also been found to bind Opa1, a bacterial outer membrane protein involved in gonococcal adherence to and invasion of human cells, suggesting a role in bacterial pathogenesis.
Novus provides other PKM2 antibodies, proteins, RNAi and lysates which can be found here. PKM2-related products are also available from Novus, including: Opa1 antibodies, PGAM1 antibodies and Pyruvate Kinase antibodies.


For more information on this PKM2 antibody or to inquire about product collaborations, please contact the Novus Product Development Team by calling 303-730-1950 or via e-mail at

Release Date: 
Friday, October 1, 2010 - 06:00